Progressive Supranuclear Palsy - A Pipeline Analysis Report by Technavio
LONDON--(BUSINESS WIRE)--May 15, 2018-- has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat progressive supranuclear palsy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180515005852/en/
Technavio has published a new pipeline analysis report on the global progressive supranuclear palsy market, including a detailed study of the pipeline molecules. (Photo: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Progressive supranuclear palsy - market overview
is commonly referred as Steele-Richardson-Olszewski syndrome. It is a rare and progressive neurodegenerative disease. Globally, out of 100,000 people, three to six have progressive supranuclear palsy. Hence, it is a classified as an orphan disease. It belongs to the tauopathy class of neurodegenerative diseases as it is associated with the pathological accumulation of tau protein in the brain. It is caused due to the gradual damage to brain cells.
According to a senior analyst at Technavio , “Progressive supranuclear palsy affects various voluntary and involuntary actions of the body such as movement, balance, speech, supranuclear vision, and the ability of swallow. People with progressive supranuclear palsy face issues that cause cognitive dysfunction. The symptoms of progressive supranuclear palsy begin between the ages of 60 and 70. Progressive supranuclear palsy is not a contagious or genetic disease.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Progressive supranuclear palsy segmentation
This market research report segments the market based on therapies employed that includes monotherapy and combination therapy, RoA (oral, intravenous, and unspecified), therapeutic modalities (monoclonal antibody, small molecule, and vaccine), targets for drugs under development (microtube-associated protein tau, O-linked N-acetylglucosaminidase (O-GlcNAcase, and unspecific), drugs under development (phase I, phase II, phase II/III, and pre-clinical), and recruitment status (unknown, recruiting, and not recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005852/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/15/2018 08:03 AM/DISC: 05/15/2018 08:03 AM